Ashwini Chand
Dr Chand completed her BSc and then pursued postgraduate studies at the University of Auckland, New Zealand where she obtained her PhD in 2006 discovering a mutation in the inhibin alpha gene functionally linked to premature ovarian failure. She then began her postdoctoral training in Australia and in 2010 was awarded a Dept. of Defense Breast Cancer Fellowship. Her research has led to the elucidation of novel mechanisms regulated by the orphan nuclear receptor LRH-1 in mammary tumour development. Dr Chand is currently a Senior Research Officer at the Cancer Drug Discovery Laboratory at Prince Henry’s Institute.
Abstracts this author is presenting: